NIH GUIDE

For Grants and Contracts

NOTICE OF MAILING CHANGE

☐ Check here if you wish to discontinue receiving this publication

☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

NIH Guide
Distribution Center
National Institutes of Health
Room B3BE07, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICIAL BUSINESS
Penalty for Private Use, $300

Third-Class Mail
Postage & Fees Paid
PHS/NIH/OD
Permit No. G-291

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 17, No. 5
February 12, 1988

Vol. 17, No. 5, February 12, 1988

NOTICES

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

NOTICES

AVAILABILITY OF FISH OIL TEST MATERIALS

P.T. 34; K.W. 0780010

National Institutes of Health

SUMMARY AND PURPOSE

The Fish Oil Test Materials Program has been established through the cooperation of the National Institutes of Health, the Alcohol, Drug Abuse, and Mental Health Administration and the National Oceanic and Atmospheric Administration-Department of Commerce. This program has been designed to provide a long-term, consistent supply of quality-assured/quality-controlled test materials to researchers in order to facilitate the evaluation of the role that omega-3 fatty acids play in health and disease.

TEST MATERIALS CURRENTLY AVAILABLE

o n-3 ethyl ester concentrate
The n-3 ester concentrate is prepared from vacuum-deodorized menhaden oil using transesterification, urea adduction and short-path distillation; the concentrate contains approximately 80 percent n-3 ethyl esters, 3 percent C18 (other than n-3), 6 percent C16 and the remainder as other esters. It is available with antioxidant additions and packaged in quantities suitable to the investigators' needs.

o Encapsulated purified steam-deodorized menhaden oil
o Encapsulated commercial preparations of corn, olive, and safflower oil
These capsules are 1-gram opaque gel capsules, packaged 100 per bottle in tamper-proof sealed brown glass bottles. Alpha-tocopherol and TBHQ antioxidants have been added to these menhaden oil capsules. The vegetable oil capsules have had no antioxidants added. However, these oils do contain endogenous tocopherols.

o Encapsulated purified steam-deodorized menhaden oil
o Encapsulated commercial preparation of corn oil
These capsules are 1 gram clear soft gel, packaged 100 per bottle in tamper-proof sealed brown glass bottles. The antioxidant content of the menhaden oil capsules and the antioxidant content of the corn oil capsules have been balanced for alpa- and gamma-tocopherol and TBHQ. These balanced levels were obtained by adding Eastman Kodak Vitamin E 5-67, GT-1 and Tenox 20A.

o Bulk vacuum-deodorized menhaden oil
The bulk menhaden oil has been winterized, alkali refined and vacuum deodorized. It is available with or without antioxidant additions and is packaged in quantities suitable to the investigators' needs. Corn oil may be purchased by the researcher; provision to quality assure the addition of antioxidants by the researcher will be made.

All products were prepared under a nitrogen blanket and will be supplied with detailed quality assurance data.

In accordance with federal regulations, an IND number will be required for the use of these materials in human studies. The Fish Oil Test Materials Advisory Committee (FOTMAC) will establish a drug master file at the Food and Drug Administration which will include manufacturing, chemical composition and toxicological data relevant to these products. Investigators awarded these materials from the FOTMAC may then reference this file in order to expedite their IND requests. Applications for omega-3 research materials for both human and animal studies will be accepted and processed.

INQUIRIES AND APPLICATIONS

Active investigators may apply for available materials to be used for relevant studies by requesting an application form from:

Nancy Hensler, Program Assistant
Fish Oil Test Materials Program
Building 31, Room 4B63
Nutrition Coordinating Committee
National Institutes of Health
Bethesda, Maryland 20892
Telephone: (301) 496-2323

THE NATIONAL INSTITUTES OF HEALTH ESTABLISHES THE NIH REVIEWERS RESERVE

P.T. 34; K.W. 1014002, 0710030

National Institutes of Health

The National Institutes of Health is establishing the NIH Reviewers Reserve (NRR), which is expected to become operational in July. Selected as needed, members of this Reserve will be able to participate fully in meetings of NIH's chartered scientific review committees that evaluate grant and cooperative agreement applications and research and development contract proposals.

The Division of Research Grants (DRG) will manage the Reserve for trans-NIH use. Nominations to the Reserve will be made by the various NIH components, primarily from among the pool of retired members of chartered NIH review committees. On behalf of the Director of NIH, the DRG Director will select, invite, and appoint highly qualified scientists and other technical experts to serve on the Reserve. Appointment to the Reserve may be for up to four years as long as members file and maintain current Form HHS 474 (Statement of Employment and Financial Interest) and do not accept appointment to any chartered Department of Health and Human Services public advisory committee. During any one grant review cycle, Reserve members may each participate with up to 2 chartered scientific review committees, at the request of the committee's Executive Secretary. The number of Reserve members that may participate in this capacity at a given chartered review committee meeting is limited to no more than one-half of the committee's quorum.

As in the past, Committee Executive Secretaries may also ask ad hoc special individual reviewers to provide advice and counsel to chartered review committees; ad hoc special reviewers do not have the rights, privileges, nor obligations or appointed committee or Reserve members and do not offer or vote on motions nor assign priority ratings.

The roster of reviewers provided as part of the summary statement (pink sheet) will list and specify appointed committee and NRR members and ad hoc consultants.

NOTICE OF MEETING - ANIMAL CARE & RESEARCH: INSTITUTIONAL RESPONSIBILITY VS. PUBLIC ACCOUNTABILITY

P.T. 42; K.W. 0201011, 1014003

Public Responsibility in Medicine and Research (PRIM&R)

Public Responsibility in Medicine and Research (PRIM&R) and Tufts University School of Veterinary Medicine are co-sponsoring a meeting in Boston on March 24-25, 1988, entitled "Animal Care & Research: Institutional Responsibility vs. Public Accountability." Topics to be addressed include: ordinances (such as the Cambridge ordinance) which propose to severely limit or restrict animal research; sunshine laws which regulate animal care committee proceedings; institutional policies affecting areas such as who can attend meetings, record keeping and in general the increasingly complex question as to how institutional responsibility and public accountability can be balanced.

For further information please contact:

PRIM&R
132 Boylston Street
Boston, Massachusetts 02116
Telephone: (617) 423-4112 or 423-1099

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

FLOW CYTOMETRY QUALITY CONTROL

RFP AVAILABLE: NIAID-AIDSP-88-26

P.T. 34; K.W. 0735005, 0760000

National Institute of Allergy and Infectious Diseases

The Epidemiology Branch, AIDS Program, National Institute of Allergy and Infectious Diseases, NIH, has a requirement for the quality control of lymphocyte phenotyping studies which are performed at extramural sites participating in collaborative AIDS clinical trials and natural history studies.

Specifically, the contractor shall be responsible for the development and implementation of a quality control program for standardization of lymphocyte counts and standardization of flow cytometry conducted at the research sites. The contractor shall also be responsible for related activities necessary to support a rigorous quality assurance program including shipment of specimens, data entry and analysis, and monitoring and review of performance at the research sites.

RFP NIH-NIAID-AIDSP-88-26 will be available on or about February 19, 1988. Responses will be due on or about April 4, 1988.

One contract will be awarded as a result of this solicitation. It is expected that the contract will have a five-year period of performance. All responsible sources may submit a proposal which will be considered by the Government.

To receive a copy of this RFP, please send 2 self addressed mailing labels to:

Jacqueline C. Holden, Contracting Officer
Contract Management Branch, NIAID
National Institutes of Health
Westwood Bldg., Room 707
5333 Westbard Avenue
Bethesda, Maryland 20892

This advertisement does not commit the Government to make an award.

CLINICAL TRIAL OF COMBINATION THERAPY OF PAPILLOMAVIRUS INFECTIONS

RFP AVAILABLE: NIAID-MIDP-88-30

P.T. 34; K.W. 0755015, 0415000, 0715125

National Institute of Allergy and Infectious Diseases

The Antiviral Substances Program, Microbiology and Infectious Diseases Program of the National Institute of Allergy and Infectious Diseases is seeking an organization to conduct several Phase I/II studies of the efficacy of combination therapy for the control of condylomata acuminatum infections. The successful offeror should be qualified to serve as the sole Contracting Unit or as the Central Unit of a collaborative trial. The successful offeror should be able to demonstrate experience in the clinical evaluation of antivirals and demonstrate a capacity to organize and administer a collaborative clinical study.

This announcement is a new solicitation. The issuance of the RFP will be on February 29, 1988, and proposals will be due at COB on April 29, 1988.

The request for the RFP should be addressed to:

Chief, Contract Management Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Westwood Building, Room 707
Bethesda, Maryland 20892

Please provide this office with two self-addressed mailing labels.

This advertisement does not commit the government to award a contract.

ANTIVIRAL SCREEN FOR HEPADNAVIRUSES, HERPESVIRUSES AND RESPIRATORY VIRUSES

RFP AVAILABLE: NIAID-MIDP-88-31

P.T. 34; K.W. 0715125, 1002045, 0760035

National Institute of Allergy and Infectious Diseases

The Development and Applications Branch, National Institute of Allergy and Infectious Diseases, seeks an organization to perform in vitro screening of compounds for their ability to inhibit the growth and/or replication of hepadnaviruses, herpesviruses (HSV, CMV, VZV) and respiratory viruses (influenza, parainfluenza, and respiratory syncytial viruses). The successful offeror(s) will provide the necessary equipment, personnel, facilities, and materials to screen annually 200 compounds for herpesviruses and 100 each for hepadnaviruses and respiratory viruses. The successful offeror(s) will be

responsible for determining the 50 percent minimum inhibitory dose, the 50 percent maximum tolerated dose, and the therapeutic index of compounds directed by the Project Officer(s). Other requirements include occasional solubility testing and storage of compounds once in solution.

This announcement, RFP NIAID-MIDP-88-31, is a new solicitation and will be available on March 10, 1988. Responses are due by April 27, 1988.

It is estimated that one contract covering all virus groups or three covering them individually will be awarded incremental for a period of five (5) years. Separate proposals for each of these three, or in any combination, will be considered.

To receive a copy of this RFP, please supply this office with two self-addressed mailing labels:

National Institute of Allergy and Infectious Diseases
National Institutes of Health
5333 Westbard Avenue
Westwood Building, Room 707
Bethesda, Maryland 20892

This advertisement does not commit the Government to award a contract.

INTERNATIONAL COLLABORATIVE STUDY OF ORAL HEALTH OUTCOMES; U.S.A. REPLICATION

RFP AVAILABLE: NIH-NIDR-4-88-1R

P.T. 34; K.W. 0785040, 0730000

National Institute of Dental Research

The National Institute of Dental Research has a requirement for the replication of the Baltimore metropolitan and non-metropolitan samples of respondents studied in 1973-1975 during the WHO "International Collaborative Study of Dental Manpower Systems in Relation to Oral Health Status (ICS-I)" to document and analyze changes in oral health structures, processes, and outcomes as may have occurred in the 10-15 year interval. A representative sample of respondents from the Baltimore metropolitan and non-metropolitan areas, ages 6-7, 12-13, 35-44, and 65-74, will be surveyed to measure both clinical oral health outcomes and appropriate socioeconomic and cultural data to permit analyses of effectiveness and efficiency of system components. It is projected that the new study, administered centrally from the WHO in Geneva, will involve seven industrialized nations and three middle-income developing nations, with each country responsible for the resources needed to collect and analyze its own data.

RFP NIH-NIDR-4-88-1R will be available on or about February 19, 1988, with proposals due on or about April 1, 1988.

The RFP package will be available upon written request to:

Marion L. Blevins, Contracting Officer
Contract Management Section, NIDR
National Institutes of Health
Westwood Building, Room 521
5333 Westbard Avenue
Bethesda, Maryland 20892

VIROLOGY QUALITY CONTROL

RFP AVAILABLE: NIAID-AIDSP-88-24

P.T. 34; K.W. 1002045, 0760015, 0755010, 0715120, 0780005

National Institute of Allergy and Infectious Diseases

The Treatment Branch, AIDS Program, National Institute of Allergy and Infectious Diseases, has a requirement for the quality control of assays of Human Immunodeficiency Virus which are performed at extramural sites participating in collaborative AIDS clinical trials and natural history studies.

Specifically, the contractor shall be responsible for the preparation of standard virus or viral gene product preparations, for distributing them to research sites, for routine quality assurance checks on virologic assays

conducted at the research sites, and for supporting the development of new assays of viral infection by field-testing their usefulness in multicenter investigations.

This is an announcement for an anticipated Request for Proposal (RFP). RFP-NIH-NIAID-AIDSP-88-24 will be issued on or about February 18, 1988, with a closing date tentatively set for April 4, 1988.

Requests for the RFP should be directed to:

Brenda J. Velez
Contracting Officer, Contract Management Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Westwood Building, Room 707
Bethesda, Maryland 20892

Please provide this office with two (2) self-addressed mailing labels.

All responsible sources may submit a proposal which shall be considered by NIAID.

This advertisement does not commit the Government to award a contract.

ACQUISITION OF DATA FOR DEVELOPING IMPROVED STRATEGIES FOR CONDITIONS OF BONE MARROW AND TO FACILITATE THE TRANSPLANTATION OF IMMUNE CELL DEPLETED MARROW GRAFTS

AVAILABLE: BROAD AGENCY ANNOUNCEMENT
NIH-NIAID-IAIDP-BAA-88-23

P.T. 34; K.W. 0705005, 0745065, 0710125

National Institute of Allergy and Infectious Diseases

The National Institutes of Health (NIH) has a requirement for the "Acquisition of Data for Developing Improved Strategies for Conditioning of Bone Marrow and to Facilitate the Transplantation of Immune Cell Depleted Marrow Grafts."

This is a notice of an anticipated BROAD AGENCY ANNOUNCEMENT. NIH-NIAID-IAIDP-BAA-88-23 was issued on or about February 10, 1988 with a closing date tentatively set for April 18, 1988.

The Genetics and Transplantation Biology Branch of the Immunology, Allergy and Immunologic Diseases Program of the National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals for the acquisition of data, through pre-clinical studies, relevant to the development of improved strategies for conditioning bone marrow to facilitate the transplantation of immuune cell depleted marrow grafts. Offerors are encouraged to submit proposals relevant to any one of the three general areas of research interest described in the Broad Agency Announcement (BAA) in accordance with the instructions in the BAA. Topics include:

Description of the host-cell population participating in the rejection of T-cell depleted bone marrow (BM), including lymphokines secreted by each population; definition of the alloantigens recognized by the cells effecting the rejection of BM; the relationship of presensitization (i.e., prior transfusion) to increased rejection; optimization of the conditioning regimen to promote BM engraftment and prevent rejection; description of agents effective in inhibiting the growth and function of cells involved in BM rejection; the role played by the marrow microenviroment, including marrow histocompatibility, in the rate of the recovery of marrow and immune function following BMT; the relationship of thymic function (i.e., age) to rate of recovery of T-cell function following the transplantation of HLA matched or mismatched BM; the role of cytokines (growth factors) IL-4 and IL-5 in the recovery of post transplant B-cell responses in recipients receiving grafts depleted of both B- and T-cells; the role of post transplant immunotherapy in the delayed onset of immune cell recovery; the role of different pretransplant conditioning regimens in altering the speed of immune cell recovery (i.e., alteration of thymic or marrow stromal cells); isolation and cultivation of pure populations of pluripotential hematopoietic stem cells; examination of the kinetics of engraftment following stem cell transplantation; and determination of the role of the pretransplant conditioning regimen and the role of specific cytokines (growth factors) in promotion of stem cell engraftment.

Three to ten contract awards are anticipated as a result of the announcement.

It is anticipated that the awards will be made on a cost reimbursement basis over a multi-year period.

All responsible sources may submit a proposal which will be considered by the agency.

To receive a copy of the BAA, please supply this office with two self-addressed mailing labels. Telephone inquiries will not be honored and all inquiries must be in writing. The BAA package will be available upon written request to:

Contracting officer
Contracts Management Branch, NIAID
National Institute of Allergy and Infectious Diseases
Westwood Building, Room 707
5333 Westbard Avenue
Bethesda, Maryland 20892

ESTABLISHMENT AND MAINTENANCE OF A SPECIFIC PATHOGEN FREE RHESUS MONKEY BREEDING AND RESEARCH PROGRAM

RFA AVAILABLE: 88-RR-01

P.T. 34; K.W. 1002002, 1002045

Division of Research Resources

Application Receipt Date: May 16, 1988

BACKGROUND

AIDS has become one of the most important diseases to affect man. The chimpanzee is the only animal model which will support the growth of HIV. The availability of chimpanzees is very limited. Several viruses which affect rhesus monkeys have many of the biological characteristics of the AIDS viruses and can be used in developing animal models which can be used for testing vaccines and chemotherapeutic drugs for treatment and prevention. Most available colonies of rhesus monkeys are naturally infected with these viruses and within colonies from 0 to almost 100 percent of the animals may have antibody to one or more of these viruses or be infected.

RESEARCH GOALS AND SCOPE

There is a need to assure that there will be a sufficient number of retrovirus-free rhesus monkeys for use in experiments to develop vaccine and drug treatments for AIDS. It is necessary to establish breeding colonies free of retroviruses and other diseases. In addition, some research activities will be supported. These will enhance production and animal quality by development of better laboratory and field tests for diagnosis of retroviruses and herpes B virus and improved housing and husbandry practices. The offspring from these colonies will be used to maintain the colony and for AIDS/SAIDS research. Available offspring are expected to be sold to investigators. A long-range program objective is that support for maintenance of Specific Pathogen Free (SPF) rhesus will be borne by users. Projects at several locations are envisioned because it may be advantageous to have several geographically dispersed colonies.

ELIGIBILITY AND REVIEW

All domestic institutions private or public that are eligible to receive PHS support and that have potential breeding facilities and animals are eligible to apply.

Applications will be received by the Division of Research Grants. Applicants must use PHS Form 398 (Revised September 1986), Application for Public Health Service Grant. A receipt date of May 16, 1988, has been established. Applications received after this date will not be accepted for review in this competition. The RFA label provided with the instructions must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review. All applications submitted in response to this RFA will be reviewed for scientific merit by a special peer review group constituted by DRR and the National Advisory Research Resources Council for program considerations.

MECHANISM OF SUPPORT

Two types of awards will be used. Awards via cooperative agreements will support breeding projects. Research grant awards will support investigator initiated research projects. Breeding and research proposals will not necessarily be awarded to the same institution. It is expected that from five to eight awards will be made in Fiscal Year 1988. The number of awards and the specific amounts of awards will depend on the merit and scope of the applications received and the availability of funds. All policies and requirements of DHHS, PHS and NIH which govern the cooperative agreements awards will apply.

INQUIRIES

A copy of the complete RFA, which describes the research goals and scope, terms and conditions, review procedures and criteria, and method of applying, may be obtained by contacting the Animal Resources Program, DRR:

Dr. William I. Gay
Chief, Animal Resources Program
Division of Research Resources
Building 31, Room 5B59
Bethesda, Maryland 20892

IN VITRO TRANSFORMATION OF HUMAN AND ANIMAL MAMMARY EPITHELIAL CELLS BY CHEMICAL OR PHYSICAL CARCINOGENS

RFA AVAILABLE: 88-CA-07

P.T. 34; K.W. 0715035, 0780015

National Cancer Institute

Application Receipt Dates: May 6, 1988 or October 17, 1988
Letter of Intent Receipt Date: March 21, 1988

The Division of Cancer Prevention and Control (DCPC), National Cancer Institute (NCI), through the Organ Systems Program (Breast Cancer), announces the availability of a Request for Applications (RFA) on the above subject.

Evidence suggests that carcinogenesis is a multistep, progressive process, with a number of heritable alterations accumulated during initiation and subsequent evolution to malignancy. It is important to define the specific alterations at each stage in this process. Toward this end, this RFA invites a search for methods by which we can succeed in obtaining efficient transformation of human and animal mammary epithelial cells to malignant cells in vitro by means of chemical or physical carcinogens. This research initiative seeks grant applications having the following objectives: (a) to define in vitro conditions that allow high frequency transformation of rodent or human mammary epithelial cells using chemical or physical carcinogens; (b) to develop in vitro culture conditions that optimally select for growth of mammary preneoplastic and neoplastic cells and favor this over growth of normal mammary cells; (c) to delineate markers (cytological, biochemical, molecular) that identify specific stages of in vitro mammary epithelial transformations and distinguish particular preneoplastic states in the multistep process; and (d) to develop improved in vivo systems for assaying tumorigenicity and to delineate functional growth assays, both in vivo and in vitro, that analyze mammary epithelial cell transformation and that correlate with tumorigenicity of the transformed cells in vivo (as, for example, in athymic, nude mice). Carefully designed studies are sought from investigators with expertise in cellular and molecular biology and experience in techniques of cell culture and transformation in vitro. The studies sought will require detailed exploration of specific experimental conditions for optimal transformation, and painstaking correlation of various phenotypic alterations with stepwise development of preneoplasia and neoplasia.

Laboratories with expertise in cell culture and in transformation are encouraged to turn their attention to mammary epithelial cell transformation by responding to this research initiative. Under this RFA, an applicant may apply for a period of support of up to five years. In addition, laboratories already involved in studies on mammary epithelial cell transformation are encouraged to expand their projects to focus on the aspects sought in this RFA; to facilitate such expanded focus, applications for appropriate supplements to ongoing NCI grants may be submitted as responses to this RFA. A response is possible on either of the two response dates, i.e., as part of either, but not both, of the two competitions. Applicants are encouraged to submit a letter of intent, and to consult with NCI program staff, before submitting an application. The letter of intent should specify which response date the applicant is choosing. It is anticipated that approximately five

awards (total over the two cycles) may be made as a result of this RFA.

Copies of the RFA may be obtained by sending a written request to:

Dr. Elizabeth P. Anderson
Breast Cancer, Organ Systems Section
Cancer Centers Branch, DCPC
National Cancer Institute, NIH
Blair Building, Room 721
Bethesda, Maryland 20892
Telephone: (301) 427-8818

The RFA label (found in the 9/86 revision of application form PHS 398) must be affixed to the bottom of the face page of the original copy of the

application. Failure to use this label could result in delayed processing of your application such that it will not reach the review committee in time for review.

SMALL GRANTS TO FACILITATE USE OF NEW TECHNIQUES OF MOLECULAR AND CELL BIOLOGY AND GENETICS BY RESEARCHERS IN DIABETES, ENDOCRINOLOGY AND METABOLIC DISEASES

RFA AVAILABLE: 88-DK-10

P.T. 34; K.W. 0715075, 1002004, 1002008, 1002019, 0785050

National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt Date: April 22, 1988

INTRODUCTION

The Division of Diabetes, Endocrinology and Metabolic Diseases (DDEM) supports basic and clinical research and research training related to diabetes mellitus and its complications, to endocrinology and a variety of endocrine disorders, and to metabolism and various metabolic diseases, including cystic fibrosis. One important area of research supported by the Division includes studies related to the molecular and cellular mechanisms of endocrine disorders including diabetes and of inherited and acquired metabolic diseases. Recent Advisory Panel meetings addressed the concern that the ability of some established investigators in these fields to pursue promising new directions in their research was impaired by their lack of experience in the newest techniques of molecular and cell biology and genetics. The Division therefore wishes to encourage established researchers who are DDEM supported Principal Investigators (PIs) or, under special circumstances a qualified member of a PI's research team, to obtain first hand experience with new techniques as a "Visiting Researcher" in the laboratory of a "Host" expert in molecular or cellular biology or genetics. The new techniques should be an integral part of an original pilot research project conceived by the Visiting Researcher in collaboration with the Host. The proposed research project must result in novel preliminary data which could strengthen a subsequent application for regular grant support.

SCOPE

This Request For Application should encourage prospective Visiting Researchers to identify Hosts in order to prepare and submit a small grant application. The application must be submitted by the Visiting Researcher and his/her Institution. The proposed research project, to be performed in the Host's laboratory, need not be directly related to endocrine or metabolic disease. However, the techniques utilized while performing the research project must be directly applicable to the Visiting Researcher's future work in diabetes, endocrinology or metabolic diseases.

OBJECTIVES

This program is intended to provide an opportunity for established investigators in diabetes endocrinology and metabolic diseases to acquire personal expertise in the utilization of one or more of the following techniques:

- o recombinant DNA techniques, including but not limited to isolation of mRNA and DNA, preparation of cDNA libraries, in situ hybridization, generation of genetic markers, restriction fragment length polymorphisms, polymerase chain reaction for gene amplification, Northern, Southern and Western blotting
- o utilization of above techniques for gene mapping and/or sequencing

- o gene transfer techniques, including vector production, transfection and infection
- o production of transgenic cells, cell lines and animals
- o hybridoma production
- o identification of gene products
- o new techniques useful for studies of cell biology including cell sorting and trafficking, signal transduction, ion channels and structure/function studies of ligand and receptor interaction
- o other novel techniques useful in diabetes, endocrinology, and metabolism

ELIGIBILITY REQUIREMENTS:

The Host must be an established investigator with expertise in molecular biology, genetics, cell biology or other novel techniques. The proposed Visiting Researcher must be a Principal Investigator on a DDEM regular research project grant (R01) or Project Director on a component of a DDEM program project grant (P01).

Under special circumstances which do not allow the DDEM supported principal investigator to visit the Host's laboratory and participate personally in the project, he/she may sponsor a qualified member of his/her team as a Visiting Researcher, provided that the team member returns to the Sponsor's laboratory for at least one year following the training.

Under such circumstances, the Sponsor will be the principal investigator and must vouch both for the research team member's qualifications and the likelihood of his/her return to the Sponsor's laboratory. The nature of the special circumstances which preclude the Sponsor's personal participation as a Visiting Researcher must also be thoroughly documented and explained in the application.

All Hosts, Visiting Researchers, or sponsored Visiting Researchers must be citizens or noncitizen nationals of the United States, or have been lawfully admitted to the United States for permanent residence.

All applicants must have received a Ph.D., M.D., or equivalent degree from an accredited domestic or foreign institution, and must have had at least seven subsequent years of relevant research or professional experience. Demonstrated research ability must be evidenced by publications and former or current grants from NIH, NSF or research foundations.

PURPOSE AND TERMS OF THE AWARD:

This non-renewable award is intended to provide a maximum of $12,500 to $25,000 for a three to six month period respectively, to be used for salaries, supply needs in the Host's laboratory, and travel funds for the Visiting Researcher. A maximum of $2,500 to $5,000 respectively is allowed for salaries of technical personnel in the Host's laboratory. A consortium agreement with the Host's institution will therefore be necessary. Further details on budget will be provided in the special instruction package for preparation of an application which must be requested from program staff (see below). The proposed activity must be full-time and must include the conduct of research with supervision provided by the Host, or by the Host in association with an expert member of the Host's staff. The activity can be scheduled throughout the year following the date of the award. The setting may be a U.S. nonprofit private or public institution, including a Federal laboratory. It is normally expected that the Host institution be different from the Visiting Researcher's institution.

We anticipate between five and ten awards under this program. However, the funding of applications submitted in response to this RFA is contingent on the actual availability of funds and receipt of applications deemed worthy of support by the accepted NIH peer review procedure.

APPLICATION AND REVIEW PROCEDURES

The format for preparing this abbreviated application is different from that used by NIH for regular research project grants. THEREFORE, BEFORE PREPARING AN APPLICATION, PROGRAM STAFF (listed below) MUST BE CONTACTED REGARDING SPECIAL INSTRUCTIONS. Applications must adhere to this format to be responsive and must be submitted on Form PHS 398 (revised 9/86), available at most institutional business offices or from the Division of Research Grants, NIH.

The RFA label (found in the 9/86 revision of application form PHS 398) must be affixed to the bottom of the face page of the original copy of the application. Failure to use this label could result in delayed processing of

your application such that it will not reach the review committee in time for review.

A single reply date of April 22, 1988, will be strictly enforced. Applications received after that day will be returned. An anticipated schedule for review and award is detailed below:

Application Receipt Date	NIDDK Special Initial Review	Earliest Award
April 22, 1988	June 1988	September 1988

REVIEW CRITERIA

A special NIDDK review committee will evaluate each application based on the following criteria: scientific significance and feasibility of the proposed pilot research project; the potential of the proposed pilot research project to provide meaningful preliminary scientific data; relevance of the techniques proposed in the research project to the Visiting Researcher's future studies in diabetes, endocrinology, or metabolism; appropriateness of the proposed research project for efficiently transferring the proposed techniques; appropriateness of ALL scientific staff involved; appropriateness of the proposed budget, considering the ability of the Visiting Researcher to obtain salary support from other sources.

REPORTING REQUIREMENTS

A Final Progress Report, an Invention Statement and a Financial Status Report must be submitted within ninety days after the termination of the award. This final reporting requirement is the same as that for other types of research grants and is in accord with 42 CFR 52 and 45 CFR 74.

CONSULTATION WITH PROGRAM STAFF

Prospective applicants are encouraged to discuss their ideas with Program staff (see below) to determine whether they fit the definition and guidelines of this announcement. Applications which, in the opinion of staff, do not meet these objectives, scope and eligibility criteria will be returned without review.

FOR FURTHER INFORMATION AND SPECIAL INSTRUCTION ON PREPARATION OF AN APPLICATION PROSPECTIVE VISITING RESEARCHERS OR SPONSORS MUST CONTACT:

For Endocrinology Research
Robert Tolman, Ph.D.
Director
Endocrinology Research
Program, NIDDK
Westwood Bldg., Room 605A
Bethesda, Maryland 20892
Telephone: (301) 496-7504

For Diabetes Research
Elaine Collier, M.D.
Assistant Director
Diabetes Research
Program, NIDDK
Westwood Bldg., Room 626
Bethesda, Maryland 20892
Telephone: (301) 496-7731

For Metabolic Research
Robert Katz, Ph.D.
Director
Metabolic Diseases Research
Program, NIDDK
Westwood Bldg., Room 607A
Bethesda, Maryland 20892
Telephone: (301) 496-7997

For Cystic Fibrosis Research
Nancy Lamontagne, Ph.D.
Director, Cystic Fibrosis Research
Program, NIDDK
Westwood Bldg., Room 607
Bethesda, Maryland 20892
Telephone: (301) 496-4980

This program is described in the Catalog of Federal Domestic Assistance, No. 13.847, Diabetes, Endocrinology, and Metabolic Diseases. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301, (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations, most specifically at 42 CFR Part 52 and CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD BUILDING IS:

5333 Westbard Avenue
Bethesda, Maryland 20816

*U.S.GOVERNMENT PRINTING OFFICE:1988-201-770:60028